The Wall Street Journal @WSJ

News that Novo Nordisk has ended its collaboration with Hims & Hers Health for its Wegovy weight-loss blockbuster treatment weighed heavily on the telehealth company's shares, sending them down 32% in afternoon trading https://t.co/aGb6Llu1SV

www.wsj.com

Hims & Hers Stock Drops More Than 30% After Novo Nordisk Breakup

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims’ compounding and deceptive marketing practices.